FibroGen, Inc.

NASDAQ:FGEN

0.32 (USD) • At close November 1, 2024
Bedrijfsnaam FibroGen, Inc.
Symbool FGEN
Munteenheid USD
Prijs 0.319
Beurswaarde 32,017,879
Dividendpercentage 0%
52-weken bereik 0.29 - 2.93
Industrie Biotechnology
Sector Healthcare
CEO Mr. Thane Wettig
Website https://www.fibrogen.com

An error occurred while fetching data.

Over FibroGen, Inc.

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the

Vergelijkbare Aandelen

Kura Oncology, Inc. logo

Kura Oncology, Inc.

KURA

16.88 USD

Cutera, Inc. logo

Cutera, Inc.

CUTR

0.587 USD

Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc.

ACRS

2.09 USD

Enanta Pharmaceuticals, Inc. logo

Enanta Pharmaceuticals, Inc.

ENTA

10.95 USD

Avid Bioservices, Inc. logo

Avid Bioservices, Inc.

CDMO

10.27 USD

Phibro Animal Health Corporation logo

Phibro Animal Health Corporation

PAHC

23.18 USD

Sana Biotechnology, Inc. logo

Sana Biotechnology, Inc.

SANA

3.66 USD

Mirum Pharmaceuticals, Inc. logo

Mirum Pharmaceuticals, Inc.

MIRM

40.4 USD

Syndax Pharmaceuticals, Inc. logo

Syndax Pharmaceuticals, Inc.

SNDX

18.98 USD

ImmunoGen, Inc. logo

ImmunoGen, Inc.

IMGN

31.235 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)